Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 5,000 shares at $124.16 ($621K) on 2018-08-14, disclosed to the SEC on 2018-08-16.
Seasonal sale ($621k) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in August in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $124.16 | 4,450 | $553K | 88.9% |
| 2 | $124.96 | 550 | $69K | 11.1% |
| Total | $124.25 avg | 5,000 | $621K | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |